S

Surgical Science Sweden AB
STO:SUS

Watchlist Manager
Surgical Science Sweden AB
STO:SUS
Watchlist
Price: 126.6 SEK -1.48%
Market Cap: 6.5B SEK
Have any thoughts about
Surgical Science Sweden AB?
Write Note

Intrinsic Value

The intrinsic value of one SUS stock under the Base Case scenario is 181.68 SEK. Compared to the current market price of 126.6 SEK, Surgical Science Sweden AB is Undervalued by 30%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SUS Intrinsic Value
181.68 SEK
Undervaluation 30%
Intrinsic Value
Price
S
Worst Case
Base Case
Best Case

Valuation Backtest
Surgical Science Sweden AB

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for SUS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about SUS?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Surgical Science Sweden AB

Provide an overview of the primary business activities
of Surgical Science Sweden AB.

What unique competitive advantages
does Surgical Science Sweden AB hold over its rivals?

What risks and challenges
does Surgical Science Sweden AB face in the near future?

Has there been any significant insider trading activity
in Surgical Science Sweden AB recently?

Summarize the latest earnings call
of Surgical Science Sweden AB.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Surgical Science Sweden AB.

Provide P/S
for Surgical Science Sweden AB.

Provide P/E
for Surgical Science Sweden AB.

Provide P/OCF
for Surgical Science Sweden AB.

Provide P/FCFE
for Surgical Science Sweden AB.

Provide P/B
for Surgical Science Sweden AB.

Provide EV/S
for Surgical Science Sweden AB.

Provide EV/GP
for Surgical Science Sweden AB.

Provide EV/EBITDA
for Surgical Science Sweden AB.

Provide EV/EBIT
for Surgical Science Sweden AB.

Provide EV/OCF
for Surgical Science Sweden AB.

Provide EV/FCFF
for Surgical Science Sweden AB.

Provide EV/IC
for Surgical Science Sweden AB.

Show me price targets
for Surgical Science Sweden AB made by professional analysts.

What are the Revenue projections
for Surgical Science Sweden AB?

How accurate were the past Revenue estimates
for Surgical Science Sweden AB?

What are the Net Income projections
for Surgical Science Sweden AB?

How accurate were the past Net Income estimates
for Surgical Science Sweden AB?

What are the EPS projections
for Surgical Science Sweden AB?

How accurate were the past EPS estimates
for Surgical Science Sweden AB?

What are the EBIT projections
for Surgical Science Sweden AB?

How accurate were the past EBIT estimates
for Surgical Science Sweden AB?

Compare the revenue forecasts
for Surgical Science Sweden AB with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Surgical Science Sweden AB and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Surgical Science Sweden AB against its competitors.

Analyze the profit margins
(gross, operating, and net) of Surgical Science Sweden AB compared to its peers.

Compare the P/E ratios
of Surgical Science Sweden AB against its peers.

Discuss the investment returns and shareholder value creation
comparing Surgical Science Sweden AB with its peers.

Analyze the financial leverage
of Surgical Science Sweden AB compared to its main competitors.

Show all profitability ratios
for Surgical Science Sweden AB.

Provide ROE
for Surgical Science Sweden AB.

Provide ROA
for Surgical Science Sweden AB.

Provide ROIC
for Surgical Science Sweden AB.

Provide ROCE
for Surgical Science Sweden AB.

Provide Gross Margin
for Surgical Science Sweden AB.

Provide Operating Margin
for Surgical Science Sweden AB.

Provide Net Margin
for Surgical Science Sweden AB.

Provide FCF Margin
for Surgical Science Sweden AB.

Show all solvency ratios
for Surgical Science Sweden AB.

Provide D/E Ratio
for Surgical Science Sweden AB.

Provide D/A Ratio
for Surgical Science Sweden AB.

Provide Interest Coverage Ratio
for Surgical Science Sweden AB.

Provide Altman Z-Score Ratio
for Surgical Science Sweden AB.

Provide Quick Ratio
for Surgical Science Sweden AB.

Provide Current Ratio
for Surgical Science Sweden AB.

Provide Cash Ratio
for Surgical Science Sweden AB.

What is the historical Revenue growth
over the last 5 years for Surgical Science Sweden AB?

What is the historical Net Income growth
over the last 5 years for Surgical Science Sweden AB?

What is the current Free Cash Flow
of Surgical Science Sweden AB?

Discuss the annual earnings per share (EPS)
trend over the past five years for Surgical Science Sweden AB.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Surgical Science Sweden AB

Current Assets 1.1B
Cash & Short-Term Investments 667.1m
Receivables 126.3m
Other Current Assets 270m
Non-Current Assets 3.9B
Long-Term Investments 5m
PP&E 75.4m
Intangibles 3.8B
Other Non-Current Assets 15.6m
Current Liabilities 256.3m
Other Current Liabilities 256.3m
Non-Current Liabilities 113.4m
Other Non-Current Liabilities 113.4m
Efficiency

Earnings Waterfall
Surgical Science Sweden AB

Revenue
838.2m SEK
Cost of Revenue
-264m SEK
Gross Profit
574.3m SEK
Operating Expenses
-426.5m SEK
Operating Income
147.8m SEK
Other Expenses
50m SEK
Net Income
197.7m SEK

Free Cash Flow Analysis
Surgical Science Sweden AB

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Surgical Science, while navigating the aftermath of an October 7 tragedy in Tel Aviv, reported minimal impact on business, with strong team cohesion and continued operations. Q3 brought a modest 3% year-over-year growth to SEK 210 million in net sales, or 1% when excluding foreign exchange effects. The highlight was in license revenues, which leapt by 38%, markedly outpacing the market's installed base and procedural growth, which registered at 13% and 19% respectively. Educational Products sales fell 9%, but adjusting for an exceptional prior U.S. order and a sluggish China market, the segment grew robustly elsewhere. Profit margins significantly improved, with profit per share skyrocketing by 65%. Despite uncertain macroeconomics, the company remains positive, observing signs of recovery in China and staying on course for their 2026 goals.

What is Earnings Call?
Fundamental Scores

SUS Profitability Score
Profitability Due Diligence

Surgical Science Sweden AB's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Positive Free Cash Flow
Positive Net Income
60/100
Profitability
Score

Surgical Science Sweden AB's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

SUS Solvency Score
Solvency Due Diligence

Surgical Science Sweden AB's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Surgical Science Sweden AB's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SUS Price Targets Summary
Surgical Science Sweden AB

Wall Street analysts forecast SUS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SUS is 189.52 SEK with a low forecast of 136.35 SEK and a high forecast of 236.25 SEK.

Lowest
Price Target
136.35 SEK
8% Upside
Average
Price Target
189.52 SEK
50% Upside
Highest
Price Target
236.25 SEK
87% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for SUS?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for SUS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

SUS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Surgical Science Sweden AB

Country

Sweden

Industry

Health Care

Market Cap

6.6B SEK

Dividend Yield

0.28%

Description

Surgical Science Sweden AB engages in the development of simulators for laparoscopic medical training. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-06-19. The systems comprise LapSim, EndoSim and TeamSim trainings. Each training combine graphics and cognitive instruction, imply navigation on touch screens and feature tactile feedback technology. The LapSim trainings consist of laparoscopic exercises that range from basic navigation to advanced suturing, the EndoSim endoscopic exercises range from functions of the scope handle and tube, to loop reduction. The TeamSim comprises procedure modules to train in a real world operation room environment and helps to build team communication skills in crisis and routine situations. The training systems are used by medical training centers and institutes worldwide for practice, validation and certification of students, surgeons, and medical doctors.

Contact

VASTRA GOTALANDS
Goeteborg
Drakegatan 7 A, 3 tr.
+46317416560.0
surgicalscience.com

IPO

2017-06-19

Employees

211

Officers

Advisor & Director
Mr. Gisli Hennermark
Chief Executive Officer
Mr. Tom Englund
Co-Founder & CTO
Mr. Anders Larsson
Chief Financial Officer
Ms. Anna Ahlberg
Chief Operating Officer
Mr. Boaz Tal ), Adv. (CPA, C.P.A.
Head of Global Sales
Mr. Martin Jansson
Show More
Executive Vice President of Products & Marketing
Ms. Inbal Mazor-Badichi
Head of Development
Mr. Daniel Evestedt
Chief Innovation Officer
Mr. Jeffrey Berkley Ph.D.
President of Research & Development
Mr. Ran Bronstein
Show Less

See Also

Discover More
What is the Intrinsic Value of one SUS stock?

The intrinsic value of one SUS stock under the Base Case scenario is 181.68 SEK.

Is SUS stock undervalued or overvalued?

Compared to the current market price of 126.6 SEK, Surgical Science Sweden AB is Undervalued by 30%.

Back to Top